Monday, February 25, 2008
Repros’ IND for the Commencement of Phase III Studies of Proellex ...
Repros’ IND for the Commencement of Phase III Studies of Proellex ...Business Wire (press release), CA - Feb 22, 2008Our lead drug, Proellex®, is a selective blocker of the progesterone receptor and is targeted for the treatment of uterine fibroids, endometriosis and ...RPRX
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment